Hyperferritinemia — Candidate Gene for Hyperferritinemia
Citation(s)
Aguilar-Martinez P, Schved JF, Brissot P The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol. 2005 May;100(5):1185-94. doi: 10.1111/j.1572-0241.2005.40998.x.
Arosio P, Levi S Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta. 2010 Aug;1800(8):783-92. doi: 10.1016/j.bbagen.2010.02.005. Epub 2010 Feb 20.
Byg KE, Milman N, Hansen S, Agger AO Serum Ferritin is a Reliable, Non-invasive Test for Iron Status in Pregnancy: Comparison of Ferritin with Other Iron Status Markers in a Longitudinal Study on Healthy Pregnant Women; Erythropoiesis. Hematology. 2000;5
Camaschella C, Poggiali E Towards explaining "unexplained hyperferritinemia". Haematologica. 2009 Mar;94(3):307-9. doi: 10.3324/haematol.2008.005405.
Cragg SJ, Wagstaff M, Worwood M Sialic acid and the microheterogeneity of human serum ferritin. Clin Sci (Lond). 1980 Mar;58(3):259-62. doi: 10.1042/cs0580259.
Finazzi D, Arosio P Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol. 2014 Oct;88(10):1787-802. doi: 10.1007/s00204-014-1329-0. Epub 2014 Aug 15.
Harrison PM, Arosio P The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203. doi: 10.1016/0005-2728(96)00022-9.
Jacobs A, Worwood M Ferritin in serum. Clinical and biochemical implications. N Engl J Med. 1975 May 1;292(18):951-6. doi: 10.1056/NEJM197505012921805. No abstract available.
Santambrogio P, Cozzi A, Levi S, Arosio P Human serum ferritin G-peptide is recognized by anti-L ferritin subunit antibodies and concanavalin-A. Br J Haematol. 1987 Feb;65(2):235-7. doi: 10.1111/j.1365-2141.1987.tb02271.x.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.